natgillin/translations-raw huggingface dataset:
Levodopa/Carbidopa/Entacapone Orion 50 mg/12.5 mg/200 mg: brownish or greyish red, round, convex unscored film-coated tablets marked with ‘LCE 50’ on one side.
Levodopa/Carbidopa/Entacapone Orion 50 mg/12,5 mg/200 mg: smećkasto ili sivkasto-crvene, okrugle, konveksne filmom obložene tablete, bez ureza, s oznakom "LCE 50" na jednoj strani.
Levodopa/Carbidopa/Entacapone Orion 75 mg/18.75 mg/200 mg film-coated tablets
Levodopa/Carbidopa/Entacapone Orion 75 mg/18,75 mg/200 mg filmom obložene tablete
Levodopa/Carbidopa/Entacapone Orion 75 mg/18.75 mg/200 mg film-coated tablets
Levodopa/Carbidopa/Entacapone Orion 75 mg/18,75 mg/200 mg filmom obložene tablete levodopa/karbidopa/entakapon
Levodopa/Carbidopa/Entacapone Orion 75 mg/18.75 mg/200 mg film-coated tablets levodopa/carbidopa/entacapone
Levodopa/Carbidopa/Entacapone Orion 75 mg/18,75 mg/200 mg filmom obložene tablete levodopa/karbidopa/entakapon
Levodopa/Carbidopa/Entacapone Orion 75 mg/18.75 mg/200 mg tablet comes in five different pack sizes (10, 30, 100, 130 or 175 tablets).
Levodopa/Carbidopa/Entacapone Orion 75 mg/18,75 mg/200 mg tablete dolazi u pet različitih veličina pakiranja (10, 30, 100, 130, ili 175 tableta).
Levodopa/Carbidopa/Entacapone Orion 75 mg/18.75 mg/200 mg: light brownish red, oval film-coated tablets marked with ‘LCE 75’ on one side.
Levodopa/Carbidopa/Entacapone Orion 75 mg/18,75 mg/200 mg: svijetlo smećkasto-crvene, ovalne filmom obložene tablete, s oznakom "LCE 75" na jednoj strani.
Levodopa/Carbidopa/Entacapone Orion comes in six different pack sizes (10, 30, 100, 130, 175 or 250 tablets).
Levodopa/Carbidopa/Entacapone Orion dolazi u šest različitih veličina pakiranja (10, 30, 100, 130, 175 ili 250 tableta).
Levodopa/Carbidopa/Entacapone Orion contains sucrose
Levodopa/Carbidopa/Entacapone Orion sadrži saharozu
Levodopa/Carbidopa/Entacapone Orion contains sucrose (1.2 mg/tablet).
Levodopa/Carbidopa/Entacapone Orion sadrži saharozu (1,2 mg/tableti).
Levodopa/Carbidopa/Entacapone Orion contains sucrose (1.4 mg/tablet).
Levodopa/Carbidopa/Entacapone Orion sadrži saharozu (1,4 mg/tableti).
Levodopa/Carbidopa/Entacapone Orion contains sucrose (1.6 mg/tablet).
Levodopa/Carbidopa/Entacapone Orion sadrži saharozu (1,6 mg/tableti).
Levodopa/Carbidopa/Entacapone Orion contains sucrose (1.89 mg/tablet).
Levodopa/Carbidopa/Entacapone Orion sadrži saharozu (1,89 mg/tableti).
Levodopa/Carbidopa/Entacapone Orion contains sucrose (1.9 mg/tablet).
Levodopa/Carbidopa/Entacapone Orion sadrži saharozu (1,9 mg/tableti).
Levodopa/Carbidopa/Entacapone Orion contains sucrose (2.3 mg/tablet).
Levodopa/Carbidopa/Entacapone Orion sadrži saharozu (2,3 mg/tableti).
Levodopa/Carbidopa/Entacapone Orion contains sucrose, and therefore patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase- isomaltase insufficiency should not take this medicine.
Levodopa/Carbidopa/Entacapone Orion sadržava saharozu te stoga bolesnici s rijetkim nasljednim problemima nepodnošenja fruktoze, malapsorpcije glukoze-galaktoze ili nedostatka saharaza- izomaltaze ne bi smjeli uzimati ovaj lijek.
Levodopa/Carbidopa/Entacapone Orion contains sucrose, and therefore patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase- isomaltase insufficiency should not take this medicine.
Levodopa/Carbidopa/Entacapone Orion sadržava saharozu te stoga bolesnici s rijetkim nasljednim problemima nepodnošenja fruktoze, malapsorpcije glukoze-galaktoze ili nedostatka saharaza-izomaltaze ne bi smjeli uzimati ovaj lijek.
Levodopa/Carbidopa/Entacapone Orion contains three active substances (levodopa, carbidopa and entacapone) in one film-coated tablet.
Levodopa/Carbidopa/Entacapone Orion sadrži tri djelatne tvari (levodopu, karbidopu i entakapon) u jednoj filmom obloženoj tableti.
Levodopa/Carbidopa/Entacapone Orion is indicated for the treatment of adult patients with Parkinson’s disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa decarboxylase (DDC) inhibitor treatment.
Levodopa/Carbidopa/Entacapone Orion je indiciran za liječenje odraslih bolesnika s Parkinsonovom bolešću, kao i za liječenje motoričkih fluktuacija na kraju intervala doziranja koje nisu stabilizirane primjenom levodope/ inhibitora dopa dekarboksilaze (DDC).
Levodopa/Carbidopa/Entacapone Orion is indicated for the treatment of adult patients with Parkinson’s disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa decarboxylase (DDC) inhibitor treatment.
Levodopa/Carbidopa/Entacapone Orion je indiciran za liječenje odraslih bolesnika s Parkinsonovom bolešću, kao i za liječenje motoričkih fluktuacija na kraju intervala doziranja koje nisu stabilizirane primjenom levodope/inhibitora dopa dekarboksilaze (DDC).
Levodopa/Carbidopa/Entacapone Orion is not recommended for the treatment of drug-induced extrapyramidal reactions
Levodopa/Carbidopa/Entacapone Orion se ne preporučuje za liječenje ekstrapiramidnih reakcija izazvanih lijekovima.
Levodopa/Carbidopa/Entacapone Orion is not recommended to be used for treatment of extrapyramidal symptoms (e.g. involuntary movements, shaking, muscle rigidity and muscle contractions) caused by other medicines.
Levodopa/Carbidopa/Entacapone Orion se ne preporučuje koristiti za liječenje ekstrapiramidnih simptoma (npr. nevoljnih pokreta, tresenja, mišićne ukočenosti i mišićnih kontrakcija) uzrokovanih drugim lijekovima.
Levodopa/Carbidopa/Entacapone Orion is used for the treatment of Parkinson’s disease.
Levodopa/Carbidopa/Entacapone Orion se koristi za liječenje Parkinsonove bolesti.
Levodopa/Carbidopa/Entacapone Orion may be taken with or without food.
Levodopa/Carbidopa/Entacapone Orion se može uzeti s ili bez hrane.
Levodopa/Carbidopa/Entacapone Orion may be taken with or without food.
Levodopa/Carbidopa/Entacapone Orion se može uzimati sa ili bez hrane.
Levodopa/Carbidopa/Entacapone Orion may have a major influence on the ability to drive and use machines.
Levodopa/Carbidopa/Entacapone Orion može imati znatan utjecaj na sposobnost upravljanja vozilima i rada sa strojevima.
Levodopa/Carbidopa/Entacapone Orion may increase the effects and side effects of certain medicines.
Levodopa/Carbidopa/Entacapone Orion može pojačati učinke i nuspojave nekih lijekova.
Levodopa/Carbidopa/Entacapone Orion may induce orthostatic hypotension.
Levodopa/Carbidopa/Entacapone Orion može izazvati ortostatsku hipotenziju.
Levodopa/Carbidopa/Entacapone Orion may lower your blood pressure, which may make you feel light-headed or dizzy.
Levodopa/Carbidopa/Entacapone Orion može sniziti krvni tlak, zbog čega možete osjetiti ošamućenost ili omaglicu.
Levodopa/Carbidopa/Entacapone Orion may make it harder for you to digest iron.
Levodopa/Carbidopa/Entacapone Orion može otežati probavu željeza.
Levodopa/Carbidopa/Entacapone Orion should not be used during pregnancy unless the benefits for the mother outweigh the possible risks to the foetus.
Levodopa/Carbidopa/Entacapone Orion se ne smije primjenjivati tijekom trudnoće, osim ako je korist za majku veća od mogućih rizika za fetus.
Levodopa/Carbidopa/Entacapone Orion therapy should be administered cautiously to patients with ischemic heart disease, severe cardiovascular or pulmonary disease, bronchial asthma, renal or endocrine disease, history of peptic ulcer disease or history of convulsions.
Liječenje Levodopa/Carbidopa/Entacapone Orionom treba provoditi uz oprez u bolesnika s ishemijskom bolešću srca, teškom kardiovaskularnom ili plućnom bolešću, bronhijalnom astmom, bubrežnom ili endokrinom bolešću, kao i u bolesnika s peptičkim ulkusom ili konvulzijama u anamnezi.
Levofloxacin
levofloksacin
Levofloxacin should be discontinued if the patient experiences symptoms of neuropathy in order to prevent the development of an irreversible condition.
Liječenje levofloksacinom mora se prekinuti u bolesnika kod kojih se pojave simptomi neuropatije kako bi se spriječio razvoj ireverzibilnih promjena.
Levonorgestrel-releasing intrauterine system
intrauterini uložak s otpuštanjem levonorgestrela
Levonorgestrel-releasing intrauterine system (IUS)
intrauterini sustav za otpuštanje levonorgestrela (intrauterini uložak)
Levonorgestrel-releasing intrauterine system (IUS)
intrauterini uložak za otpuštanje levonorgestrela
levothyroxine (to stimulate the thyroid gland)
levotiroksin (za stimulaciju štitne žlijezde)
Lexington MA 02421 USA
Lexington MA 02421 SAD
Lexington, MA 02421 USA
Lexington, MA 02421 SAD
LFTs should be performed prior to the initiation of treatment with Eucreas in order to know the patient’s baseline value.
Testove jetrene funkcije treba napraviti prije početka liječenja Eucreasom kako bi se utvrdile početne vrijednosti.
LFTs should be performed prior to the initiation of treatment with Icandra in order to know the patient’s baseline value.
Testove jetrene funkcije treba napraviti prije početka liječenja Icandrom kako bi se utvrdile početne vrijednosti.
LFTs should be performed prior to the initiation of treatment with Zomarist in order to know the patient’s baseline value.
Testove jetrene funkcije treba napraviti prije početka liječenja Zomaristom kako bi se utvrdile početne vrijednosti.
LH stimulates ovulation during your menstrual cycle.
LH stimulira ovulaciju tijekom vašeg menstrualnog ciklusa.
LH stimulates the release of the eggs.
LH stimulira otpuštanje jajnih stanica.
LHON can lead to loss of eyesight due to the inactivity of cells responsible for vision.
LHON može rezultirati gubitkom vida uslijed neaktivnosti stanica odgovornih za vid.
LHRH controls another hormone, called LH (‘luteinising hormone’).
LHRH nadzire drugi hormon, zvan LH („luteinizirajući hormon“).
LHRH controls the production and release of another hormone called luteinising hormone (LH), which causes ovulation.
LHRH upravlja proizvodnjom i otpuštanjem drugog hormona koji se naziva luteinizirajući hormon (LH), koji uzrokuje ovulaciju.
Libertek 500 micrograms film-coated tablets are yellow, D-shaped film-coated tablets, embossed with 'D' on one side.
Libertek 500 mikrograma filmom obložene tablete su žute filmom obložene tablete u obliku slova D, s utisnutim “D” s jedne strane.
Libertek 500 micrograms film-coated tablets roflumilast
Libertek 500 mikrograma filmom obložene tablete roflumilast
Libertek is not indicated as rescue medicinal product for the relief of acute bronchospasms.
Libertek nije indiciran kao lijek za hitno ublažavanje akutnog bronhospazma.
Libertek is not recommended if you have one or more of the following diseases: severe immunological diseases such as HIV infection, multiple sclerosis (MS), lupus erythematosus (LE) or progressive multifocal leukoencephalopathy (PML)
Libertek se ne preporučuje ako imate jednu ili više sljedećih bolesti: tešku imunološku bolest poput HIV-infekcije, multiple skleroze (MS), eritemskog lupusa (LE) ili progresivne multifokalne leukoencefalopatije (PML)
Libertek is not used on its own but as an ‘add-on’ to treatment with bronchodilators (medicines that widen the airways in the lungs).
Libertek se ne koristi kao samostalni lijek nego kao dodatak liječenju bronhodilatatorima (lijekovima koji šire dišne puteve u plućima).
Libertek should not be used by children and adolescents under 18 years of age.
Libertek nije namijenjen djeci i adolescentima mlađim od 18 godina.
Libido decreased
manjeni libido
Libido decreased
smanjeni libido
Libido decreased Mood altered
poremećaj spavanja, bruksizam, smanjeni libido,
libido decreased myalgia
manjeni libido mialgija
Libido increased
pojačani libido
Licensed smallpox vaccine
Odobreno cjepivo protiv velikih boginja
lichenoid keratosis (lichen planus and lichen sclerosus)
lihenoidna keratoza (lichen planus i lichen sclerosus)
lichenoid keratosiso, psoriasis, alopecia, erythema nodosum, dermatitis, hair colour changes, papule
lihenoidna keratozao, psorijaza, alopecija, nodozni eritem, dermatitis, promjene boje kose, papule
LID OF TRAY CONTAINING 30 SINGLE-DOSE CONTAINERS
PLITICA KOJA SADRŽI 30 JEDNODOZNIH SPREMNIKA
lidocaine (intravenous)
lidokain (intravenski)
Lidocaine (systemic)
dronedarona, sistemskog lidokaina,
Lidocaine (systemic) Quinidine Hydroquinidine (saquinavir/ritonavir)
Lidokain (sistemski) Kinidin Hidrokinidin (sakvinavir/ritonavir)
Lidocaine and prilocaine are excreted in human milk, but at therapeutic doses of Fortacin no effects on the breastfed newborns/infants are anticipated due to active substance transfer from the male patient to his female partner.
Lidokain i prilokain izlučuju se majčino mlijeko, ali u terapijskim dozama lijeka Fortacin ne očekuje se učinak na dojenu novorođenčad/dojenčad s obzirom na prijenos djelatne tvari od muškog pacijenta na njegovu partnericu.
lidocaine given by injection
lidokain primijenjen injekcijom
Lidocaine is largely metabolised in the liver by cytochrome P450 (CYP 3A4) and probably to a minor extent in the skin.
Lidokain se opsežno metabolizira u jetri putem citokroma P450 (CYP 3A4) i vjerojatno putem kože, u manjoj mjeri.
Lidocaine is reported to be 66% bound by plasma proteins, including alpha-1-acid glycoprotein.
Prijavljeno je da se 66 % lidokaina veže uz proteine plazme, uključujući alfa-1 kiseli glikoprotein.
Lidocaine toxicity (neurological and cardiac adverse events) has been reported following co-administration with propranolol.
U istodobnoj primjeni s propranololom pokazala se toksičnost lidokaina (neurološke i srčane nuspojave).
Lidocaine was not genotoxic and the carcinogenic potential of lidocaine has not been studied.
Lidokain nije bio genotoksičan, a njegov karcinogeni potencijal nije bio proučen.
Lidocaine:  expected
Amprenavir: Cmax 
Lidocaine:  expected
Amprenavir: očekuje se 
Life threatening air or gas embolism has occurred with the use of spray devices employing pressure regulators to administer the fibrin sealant.
Po život opasne zračna ili plinska embolija javila se pri uporabi raspršivača koristeći regulator tlaka za primjenu fibrinskog tkivnog ljepila.
Life threatening allergic reaction
alergijska reakcija opasna po život
Life threatening and fatal infectious complications including necrotising fasciitis and sepsis have been observed in patients treated with Vectibix (see section 4.4).
Kod bolesnika liječenih lijekom Vectibix opažene su komplikacije u obliku infekcija opasnih po život i sa smrtnim ishodom, uključujući nekrotizirajući fasciitis i sepsu (vidjeti dio 4.4).
Life threatening and fatal infectious complications including necrotising fasciitis and sepsis have been observed in patients treated with Vectibix.
Kod bolesnika liječenih lijekom Vectibix opažene su komplikacije u obliku infekcija opasnih po život i sa smrtnim ishodom, uključujući nekrotizirajući fasciitis i sepsu.
life threatening cardiac arrhythmia
zbog srčane aritmije koja može
life threatening complications of uncontrolled diabetes
po život opasne komplikacije nekontrolirane šećerne bolesti
life threatening complications of uncontrolled diabetes, low blood sugar, excessive drinking of water
po život opasne komplikacije nekontrolirane šećerne bolesti, nizak šećer u krvi, prekomjerno pijenje vode
Life threatening events and fatal outcomes associated with hypocalcaemia have been reported in adult and paediatric patients treated with cinacalcet.
Životno opasni događaji i smrtni ishodi povezani s hipokalcemijom zabilježeni su u odraslih i pediatrijskih bolesnika liječenih sinakalcetom.
Life threatening events and fatal outcomes associated with hypocalcaemia have been reported in adult and paediatric patients treated with Mimpara.
Životno opasni događaji i smrtni ishodi povezani s hipokalcemijom zabilježeni su u odraslih i pediatrijskih bolesnika liječenih Mimparom.
Life threatening events and fatal outcomes associated with low calcium levels (hypocalcaemia) have been reported in patients treated with Mimpara.
U bolesnika liječenih Mimparom zabilježeni su događaji opasni po život i smrtni ishodi povezani s niskim razinama kalcija (hipokalcemijom).
Life threatening haemorrhages 60-100 Repeat infusion every 8 to 24 hours until threat is resolved
Krvarenja opasna po život 60-100 Ponavljati infuziju svakih 8 do 24 sata do otklanjanja opasnosti.
Life threatening haemorrhages 60–100 Repeat infusion every 8 to 24 hours
Krvarenja opasna po život 60 – 100 Ponovite infuziju svakih 8 – 24 sati
Life threatening haemorrhages, deep muscle bleeding including iliopsoas
Krvarenja opasna po život, krvarenje duboko u mišiću uključujući bočno- slabinski mišić
Life threatening haemorrhages, deep muscle bleeding including iliopsoas
Krvarenja opasna po život, krvarenje duboko u mišiću uključujući bočno- slabinski mišić)
Life threatening haemorrhages.
Krvarenja opasna po
Life threatening skin rash (including Stevens-Johnson syndrome or toxic epidermal necrolysis) or severe widespread pruritus interfering with activities of daily living or requiring medical intervention
Životno opasan kožni osip (uključujući Stevens-Johnsonov sindrom ili toksičnu epidermalnu nekrolizu) ili jaki, prošireni svrbež koji ometa bolesnika u svakodnevnim aktivnostima ili zahtijeva liječničku intervenciju
Life-threatening
Krvarenja opasna po život
Life-threatening air or gas embolism has occurred with the use of spray devices employing a pressure regulator to administer EVICEL.
Kod primjene lijeka EVICEL putem raspršivača koji koriste regulator tlaka došlo je do po život opasne zračne ili plinske embolije.
Life-threatening air or gas embolism has occurred with the use of spray devices employing pressure regulator to administer EVICEL.
Kod primjene lijeka EVICEL pomoću raspršivača koji su koristili regulator tlaka došlo je do po život opasne zračne ili plinske embolije.
Life-threatening air or gas embolism has occurred with the use of spray devices employing pressure regulator to administer EVICEL.
Kod primjene lijeka EVICEL putem raspršivača koji su koristili regulator tlaka došlo je do po život opasne zračne ili plinske embolije.
life-threatening allergic reaction (anaphylactic shock).
po život opasna alergijska reakcija (anafilaktički šok);
Life-threatening allergic reactions
po život opasne alergijske reakcije
Life-threatening Anaphylactic/Anaphylactoid reactions*
po život opasne anafilaktičke/anafilaktoidne reakcije
life-threatening and fatal allergic reactions (anaphylactic/anaphylactoid hypersensitivity)
po život opasne i smrtonosne alergijske reakcije (anafilaktička/anafilaktoidna preosjetljivost)
Life-threatening bleeds
Po život opasno krvarenje
Life-threatening consequences, urgent intervention indicated
Posljedice opasne po život, indicirana je hitna medicinska intervencija.
Life-threatening cutaneous reactions (Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) and drug rash with eosinophilia and systemic symptoms (DRESS)) have been reported with the use of PROTELOS.
Pri primjeni PROTELOS-a zabilježeni su slučajevi po život opasnih kožnih reakcija (Stevens- Johnsonov sindrom (SJS), toksična epidermalna nekroliza (TEN) i osip uzrokovan lijekom uz eozinofiliju i sustavne simptome (DRESS).
Life-threatening haemorrhages 60-100 Repeat infusion every 8-24 hours until threat is resolved.
Životno opasna krvarenja 60-100 Ponoviti infuziju svakih 8-24 sata do prestanka prijetnje.
Life-threatening haemorrhages.
Krvarenja opasna po
Life-threatening haemorrhages:
Krvarenja opasna po život
Life-threatening infection of the soft tissue including the ano-genital region.
Po život opasne infekcije mekog tkiva, uključujući i područje spolnih organa i anusa.
Life-threatening infection;
Infekcija koja ugrožava život;
life-threatening irregular heart beat,
za život opasni nepravilni otkucaji srca,
life-threatening reactions such as
kolhicinom poput neuromuskularne
Life-threateningc
životno ugrožavajućec
Life-threateningd
životno ugrožavajućed
Lifecare 5000 Plumset Microdrip, Abbott
Lifecare 5000™ Plumset Microdrip, Abbott
Lifepharma (Z.A.M.) Ltd
Lifepharma (ZAM) Ltd
Lift here
Podići ovdje
Lift here to open
Podignuti ovdje da biste otvorili.
Lift here to open.
Podignuti ovdje da biste otvorili.
Lift off plastic vial adapter packaging, leaving vial adapter on vial.
Ukloite plastično pakiranje nastavka za bočicu; nastavak ostaje na bočici.
Lift the blister tray straight up so that it comes off the vial adapter.
Podignite blister posudicu prema gore tako da se skine s nastavka za bočicu.
Lift the pen from your injection site.
Podignite brizgalicu sa mjesta injekcije.
Lift the Plegridy pen from the injection site.
Podignite Plegridy brizgalicu s mjesta injekcije.
Lift the pre-filled pen from the injection site.
Podignite napunjenu brizgalicu s mjesta injekcije.
Light anaesthesia:
Plitka anestezija:
Light beige, opaque, oval, soft gelatine capsules, imprinted with black logo “AlO”, filled with a clear yellowish solution.
Svijetlo bež, neprozirna, ovalna, meka želatinska kapsula s utisnutom crnom oznakom “AlO”, ispunjena bistrom, žućkastom otopinom.
Light blue
vijetloplava
Light blue capsule-shaped tablets, printed with “V 150” in black ink on one side and plain on the other (16.5 mm x 8.4 mm in modified caplet shape).
Svijetloplave tablete u obliku kapsula, s oznakom “V150” otisnutom crnom tintom na jednoj strani i bez oznaka na drugoj (16,5 mm x 8,4 mm u obliku kapsule).
Light blue capsules, size 1, approximately 19 mm, imprinted “OPC 25” on the cap and “Bial” on the body.
Kapsule svijetloplave boje, veličine 1, duga oko 19 mm, s otisnutim „OPC 25” na kapici i „Bial” na tijelu kapsule.
Light blue size 0 hard capsules imprinted “75 mg” in white ink and a dark blue cap imprinted with Raptor Logo in white ink.
Svijetloplave kapsule veličine 0 s oznakom ,,75 mg" otisnutom bijelom tintom i tamnoplavom kapicom s logotipom tvrtke Raptor otisnutim bijelom tintom.
Light blue size 3 hard capsules imprinted “25 mg” in white ink and a light blue cap imprinted with Raptor Logo in white ink.
Svijetloplave kapsule veličine 3 s oznakom ,,25 mg" otisnutom bijelom tintom i svijetloplavom kapicom s logotipom tvrtke Raptor otisnutim bijelom tintom.
Light blue to blue, capsule shaped tablet, debossed with "93" on one side and “210” on the other side.
Svijetloplava do plava tableta oblika kapsule, s utisnutom oznakom „93“ na jednoj strani te „210“ na drugoj strani tablete.
Light blue, round, film-coated tablets with beveled edges (diameter: 6.5 mm, thickness: 2.3–3.5 mm).
Svijetlo plave, okrugle, filmom obložene tablete s ukošenim rubovima (promjera: 6,5 mm, debljine: 2,3-3,5 mm).
Light blue, round, film-coated tablets with beveled edges (diameter: 6.5 mm, thickness: 2.3–3.5 mm).
Svijetlo plave, okrugle, filmom obložene tablete ukošenih rubova (promjera: 6,5 mm, debljine: 2,3- 3,5 mm).
Light brown and green, opaque hard capsule with the marking “ROCHE” and the code “0245” on each half of the capsule shell.
Svijetlosmeđe i zelene neprozirne tvrde kapsule s oznakom “ROCHE” i šifrom “0245” na obje polovice ovojnice kapsule.
Light brown oval biconvex tablet with a score line on one face and plain on the other.
Svijetlo smeđe ovalne bikonveksne tablete s razdjelnom crtom na jednoj strain i ravne na drugoj.
Light brown to brown, biconvex, round, film-coated tablets, with “2.5/850” printed on one side and “4246” printed on the other side, in blue ink.
Svijetlosmeđe do smeđe, bikonveksne, okrugle, filmom obložene tablete koje imaju plavom tintom otisnutu oznaku „2.5/850“ na jednoj i „4246“ na drugoj strani.
Light brown, biconvex, ellipse-shaped film-coated tablets with approximately 18 mm length and 10 mm width, embossed ‘E200’ on one side, plain on the other side.
Svijetlosmeđe, bikonveksne, filmom obložene tablete eliptičnog oblika, duljine oko 18 mm i širine 10 mm, s otisnutom oznakom "E200" na jednoj strani te bez oznake na drugoj strani.
Light brown, oval, approximately 15.6 mm × 7.8 mm, biconvex film-coated tablet debossed with “AV3” on one side and “M” on the other side.
Svjetlosmeđa, ovalna, bikonveksna filmom obložena tableta dimenzija približno 15,6 mm × 7,8 mm s utisnutom oznakom „AV3“ na jednoj strani i „M“ na drugoj strani.
Light brownish red, oval film-coated tablets marked with ‘LCE 125’ on one side.
Svijetlo smećkasto-crvene, ovalne filmom obložene tablete, s oznakom "LCE 125" na jednoj strani.
Light brownish red, oval film-coated tablets marked with ‘LCE 75’ on one side.
Svijetlo smećkasto-crvene, ovalne filmom obložene tablete, s oznakom "LCE 75" na jednoj strani.